 vivo thrombin inhibition enhances arterial recanalization recombinant tissue-type plasminogen activator effects heparin synthetic competitive thrombin inhibitor yl acid monohydrate Argatroban thrombolysis recombinant tissue-type plasminogen activator rt-PA groups rabbits arterial thrombosis model whole-blood clot isolated femoral arterial segment superimposed endothelial damage distal high-grade stenosis rt-PA intravenous bolus mg/kg body intervals recanalization maximum boluses rabbits intravenous injection mg/kg aspirin rt-PA induced transient reflow animal rabbits intravenous heparin units/kg minutes rt-PA administration reflow animals persistent rabbits administration aspirin heparin rabbits similar rt-PA-induced recanalization rt-PA administration rabbits intravenous Argatroban micrograms/kg/min minutes recanalization persistent patency rabbits aspirin Argatroban rt-PA recanalization persistent patency animals Argatroban minutes heparin minutes reflow boluses rt-PA combination Argatroban median value bolus heparin median value boluses reocclusion reflow frequent Argatroban versus rabbits degree thrombolysis pathological analysis extensive Argatroban heparin patency observation period elimination Argatroban circulation Argatroban relative enhances sustains thrombolysis rt-PA promise adjunctive agent thrombolytic therapy arterial thrombosis